NEW YORK – Bio-Techne on Monday said that it has partnered with Alzpath to develop the Simple Plex Human Phospho-Tau (T217) Alzpath Assay for neurodegenerative disease research.
The assay uses Bio-Techne's Ella immunoassay instrument and Alzpath's proprietary phosphorylated Tau217 antibody to detect the pTau217 signal in 90 minutes from less-invasive sample types, such as plasma. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, which are key features of Alzheimer's disease. Recent research has shown that blood-based pTau217 has the strongest relationship with the hallmarks of Alzheimer's disease compared to other biomarkers.
"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," Alzpath CEO Chad Holland said in a statement. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."
Roche and Beckman Coulter have both licensed Alzpath's pTau217 antibody for use in blood-based Alzheimer's diagnostic tests.